Cytotoxicity of daunorubicin in trisomic (+21) human fibroblasts: Relation to drug uptake and cell membrane fluidity

Cell Biology International

Volumn 25, Issue 2, 2001, Pages 157-170

  Przybylska, Maria ^a   Koceva Chyla, Aneta ^a   Rózga, Blazej ^a   Józwiak, Zofia ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

12 AS; Cell membrane fluidity; Cytotoxicity; Daunorubicin; Down's syndrome; Fibroblasts; Intracellular accumulation; TMA DPH

Indexed keywords

DAUNORUBICIN;

ANISOTROPY; ARTICLE; CELL MEMBRANE; CELL MEMBRANE FLUIDITY; CELL SURVIVAL; CELLULAR DISTRIBUTION; CHROMOSOME 21; CONTROLLED STUDY; CYTOTOXICITY; DOWN SYNDROME; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG PROTEIN BINDING; DRUG UPTAKE; GROWTH INHIBITION; HUMAN; HUMAN CELL; MEMBRANE FLUIDITY; SKIN FIBROBLAST; TRISOMY 21;

EID: 0034979987     PISSN: 10656995     EISSN: None     Source Type: Journal    
DOI: 10.1006/cbir.2000.0583     Document Type: Article

References (95)

1. Characterisation of daunorubicin resistance in K562 leukemia cells lacking daunorubicin reductase activity
2. Kinetic transport analysis of daunorubicin by LoVo and LoVo/DX cells
3. Fluorometric determination of the kinetics of anthracyclines uptake by cells
4. Cell membranes as target for anticancer agents
5. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction
6. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells
7. Gene dosage effect in trisomy 21
8. Chromosome rearrangement in acquired malignant diseases
9. The role of alterations in free radical metabolism in mediating cognitive impairments in Down's syndrome
10. Chromosome 7 abnormalities in children with Down syndrome and leukemia
11. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV 40 DNA: Relationship with DNA affinity and cytotoxicity
12. Evaluation of tetrazolinum-based semi-automated colorimetric assay: Assessment of chemosensitivity testing
13. Molecular recognition of DNA by daunorubicin. Anthracycline Antibiotics New Analogues, Methods of Delivery and Mechanism of Action
14. Transverse location of anthracyclines in lipid bilayers. Paramagnetic quenching studies
15. Daunorubicin-induced cardiac injury in the rabbit: A role for daunorubicinol?
16. Cell membranes as targets for anti-cancer drug action
17. Complex karyotype and N-RAS point mutation in case of acute megakaryoblastic leukemia (M7) following a myelodysplastic syndrome
18. Prevention of doxorubicin-induced killing of MCF-7 human breast cancer cells by oxygen radical scavengers and iron chelating agents
19. Anthracyclines and anthracenediones
20. Disruption of cellular signaling pathway by daunorubicin through destabilisation of nonlamellar membrane structures
21. Leukemia in trisomy 21 mosaic: Specific involvement of the trisomic cells
22. Atypical background somatic mutant frequencies at the HPRT locus in children and adults with Down syndrome
23. Down's syndrome and leukemia: Epidemiology, genetics, cytogenetics and mechanism of leukemogenesis
24. Comparison of the membrane transport of anthracycline derivatives in drug-resistant and drug-sensitive K562 cells
25. Determination of osmotic active drug concentration in the cytoplasm of anthracycline-resistant and K562 cells
26. Permeability of lipid bilayer to anthracycline derivatives. Role of the bilayer composition and of the temperature
27. Erythrocyte antioxidant system in Down syndrome
28. A differential interaction of daunomycin, adriamycin and their derivatives with human erythrocytes and phospholipid bilayers
29. Induction of resistance to daunorubicin in drug sensitive leukemia P388 cells: A role of PKCβI isosyme
30. Protection against daunorubicin cytotoxicity by expression of a cloned human carbonyl reductase cDNA in K562 leukemia cells
31. Generation of free radicals and lipid peroxidation by redox cycling of adriamycin and daunomycin
32. Meiotic origin of trisomic neoplasms
33. Increased frequency of chromosome abnormalities in fibroblasts from hairy cell leukemia patients
34. A cytogenetic study of 1000 spontaneous abortions
35. Numerical chromosome aberrations in human neoplasia
36. Significance of trisomy 7 in thyroid tumours
37. Anthracyclines in the treatment of cancer
38. The efficacy of the anthracycline prodrug daunorubicin-GA3 in human ovarian cancer xenografts
39. Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: Involvement of free radicals
40. Leukaemia and transient leukaemia in Down syndrome
41. Alterations in erythrocyte membrane fluidity in children with trisomy 21: A fluorescence study
42. Favorable in vitro drug resistance profiles in children with down syndrome and acute leukemia, both in ALL and ANLL
43. Effect of endogenous glutathione, superoxide dismutases, catalase, and glutathione peroxidase on adriamycin tolerance of Chinese hamster ovary cells
44. Down's syndrome: A pathology involving the lack of balance of reactive oxygen species
45. Down's syndrome increased enzymatic antioxidative defence is accompanied by decreased superoxide anion generation in blood
46. Gamma-radiation sensitivity of fibroblast DNA in trisomy 21
47. Myelodisplastic syndrome with translocation (8; 21): A distinct myelodisplastic syndrome entity or M2-acute myeloid leukemia with extensive myeloid maturation
48. Down's syndrome: Permeability of the erythrocyte membrane for spin labelled non-electrolytes
49. Plasma membrane fluidity measurements in whole living cells by fluorescence anisotropy of trimethylammonium-diphenylhexatriene
50. Acute lymphoblastic leukaemia
51. Cell membrane fluidity and adriamycin retention in tumour progression model of AKR lymphoma
52. Human carbonyl reductase (CBR) localised to band 21q22.12 by high-resolution fluorescence in situ hybridisation displays gene dosage effects in trisomy 21 cells
53. Base specific and regioselective chemical cross-linking of daunorubicin to DNA
54. Trisomy 10 in acute myeloid leukemia: Report of a new case
55. Trisomy 5 in two cases of acute monocytic leukemia with hyperdiploid clones
56. Semiquinone free radical formation by daunorubicin aglycone incorporated into the cellular membranes of intact Chinese Hamster Ovary cells
57. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, Daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells
58. Plasma membrane as a site of redox activation of daunomycin in intact human erythrocytes. Quantitative evaluation of the hydrogen peroxide produced by the membrane with respect to the cytosol
59. Daunorubicin uptake by leukaemia cells: Correlation with treatment outcome and mdr 1 expression
60. Role of free radicals in an adriamycin-resistant human small cell lung cancer cell line
61. Congenital abnormalities in children with acute leukemia: A report from the Children's Cancer Group
62. Childhood cancer
63. Report of the committee on chromosome changes in neoplasia
64. A plasma membrane 'vacuum cleaner' for daunorubicin in non-P-glycoprotein multidrug-resistant SW-1573 human non-small cell lung carcinoma cells. A study using fluorescence resonance energy transfer
65. Transport mechanism of anthracycline derivatives in human leukemia cell lines: Uptake of pirarubicin daunorubicin and doxorubicin by K562 and multidrug-resistant K562/ADM cells
66. Origin and mechanisms of non-disjunction in human autosomal trisomies
67. 2; an explanation for the cardiotoxicity of anthracycline antibiotics
68. Reduction of drug ketones by dihydrodiol dehydrogenases, carbonyl reductase and aldehyde reductase of human liver
69. Roles of reactive oxygen species and antioxidant enzymes in murine daunomycin-induced nephropathy
70. Hypersensitivity to jonizing radiation in cultured cells from Down syndrome patients
71. Antioxidant enzymes and fatty acid status in erythrocytes of Down's syndrome patients
72. Nuclear magnetic resonance studies of lecithin bimolecular leaflets with incorporated fluorescent probes
73. Chromosome abnormalities and maternal age
74. Free radical formation by antitumour quinones
75. Influence of daunorubicin on membrane permeability properties: Detection by means of intracellular accumulation and efflux of fluorescein
76. Carbonyl reduction of daunorubicin in rabbit liver and heart
77. Clinical characteristic and treatment outcome of children with acute lymphatic leukemia and Down's syndrome
78. Trisomy 21 and accelerated aging: DNA-repair parameters in peripheral lymphocytes of Down's syndrome patients
79. Oxygen radical detoxification enzymes in doxorubicin-sensitive and -resistant P388 murine leukemia cells
80. Down syndrome and leukemia
81. Effect of carminomycin on the viability of fibroblasts from patients with regular trisomy 21
82. Sensitivity of trisomic-21 human fibroblasts to gamma-radiation and carminomycin
83. The significance of trisomy 8 in de novo acute myeloid leukaemia: The accompanying chromosome aberrations determine the prognosis
84. Binding of daunomycin to acidic phospholipids
85. Intracellular localisation, vesicular accumulation and kinetics of daunorubicin in sensitive and multidrug-resistant gastric carcinoma EPG85-257 cells
86. The environmental basis of the Down syndrome phenotype
87. Redox pathway leading to the alkylation of DNA by the anthracycline antitumour drugs adriamycin and daunomycin
88. Anthracycline incorporation in human lymphocytes. Kinetics of uptake and nuclear concentration
89. Expression of Chromosome 21-Localized Genes in Acute Myeloid Leukemia: Differences Between Down syndrome and Non-Down Syndrome Blast Cells and Relationship to In Vitro Sensitivity to Cytosine Arabinoside and Daunorubicin
90. Enhanced metabolism of 1-beta-D-arabinofuranosylcytosine in Down syndrome cells: A contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia
91. Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to cytosine arabinose and daunorubicin
92. Biomembrane structure and function viewed by fluorescence
93. Interaction of antitumour drug daunomycin with DNA in solution and at the surface